JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer
1-866-373-1464
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer
- Sex: Male
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Prostate
Study Purpose
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.
- UH IRB: STUDY20250799
- StudyID: JAN1825
- ClinicalTrials.gov: NCT07082920
1-866-373-1464
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-866-373-1464